Inclusion Criteria: - Adult patients, >/= 18 years of age - Histologically confirmed Stage III or IV recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) - Progressive disease on or after first-line platinum-based chemotherapy regimen for R/M SCCHN (maximum of 6 cycles) - No more than one platinum-based chemotherapy regimen for R/M SCCHN is allowed - Prior platinum-based treatment as definitive chemo/radiotherapy for locally advanced disease is allowed if completed/terminated >/= 6 months before the platinum-based regimen for R/M SCCHN - Consent to provide archival tumor tissue for biomarker testing - Measurable disease per RECIST v1.1 - ECOG performance status of 0, 1 or 2 - Adequate hematologic, renal and liver function Exclusion Criteria: - Nasopharyngeal cancer - Prior treatment with an investigational or approved agent for the purpose of inhibiting HER family members - This includes but is not limited to cetuximab, panitumumab, erlotinib, geftinib, and lapatinib - Prior treatment with an EGFR inhibitor is allowed if it was administered as part of definitive therapy for locally advanced disease and completed >/=1 year before study enrollment - Leptomeningeal disease as the only manifestation of the current malignancy - Active infection requiring iv antibiotics - Active autoimmune disease that is not controlled by non-steroidal anti-inflammatory drugs - Current severe, uncontrolled systemic disease (e.g. clinically significant cardiovascular, pulmonary, or metabolic disease; wound healing disorders; ulcers; bone fractures) - History of heart failure or serious cardiac arrhythmia - History of myocardial infarction within 6 months of Cycle 1, Day 1 - Clinically significant liver disease, including active viral, alcoholic or other hepatitis, cirrhosis, or current alcohol abuse - HIV infection - Primary central nervous system (CNS) malignancy or untreated/active CNS metastases (progressing or requiring anticonvulsants or corticosteroids for symptomatic control) - Pregnant or lactating women - Malignancies other than SCCHN within 5 years prior to randomization, with the exception of adequately treated basal or squamous cell skin cancer and carcinoma in situ of the cervix